journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/29346498/association-of-treatment-for-hodgkin-lymphoma-with-estrogen-receptor-status-of-subsequent-breast-cancers
#1
Diana R Withrow, Lindsay M Morton, Rochelle E Curtis, Sara J Schonfeld, Amy Berrington de González
No abstract text is available yet for this article.
January 18, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29346484/association-of-dietary-inflammatory-potential-with-colorectal-cancer-risk-in-men-and-women
#2
Fred K Tabung, Li Liu, Weike Wang, Teresa T Fung, Kana Wu, Stephanie A Smith-Warner, Yin Cao, Frank B Hu, Shuji Ogino, Charles S Fuchs, Edward L Giovannucci
Importance: Inflammation is important in colorectal cancer development. Diet modulates inflammation and may thus be a crucial modifiable factor in colorectal cancer prevention. Objective: To examine whether proinflammatory diets are associated with increased colorectal cancer risk by using an empirical dietary inflammatory pattern (EDIP) score based on a weighted sum of 18 food groups that characterizes dietary inflammatory potential based on circulating levels of inflammation biomarkers...
January 18, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29346478/differentiation-syndrome-associated-with-enasidenib-a-selective-inhibitor-of-mutant-isocitrate-dehydrogenase-2-analysis-of-a-phase-1-2-study
#3
Amir T Fathi, Courtney D DiNardo, Irina Kline, Laurie Kenvin, Ira Gupta, Eyal C Attar, Eytan M Stein, Stephane de Botton
Importance: Enasidenib mesylate, a mutant isocitrate dehydrogenase 2 (IDH2) protein inhibitor that promotes differentiation of leukemic myeloblasts, was recently approved by the US Food and Drug Administration for use in relapsed/refractory (R/R) mutant IDH2 acute myeloid leukemia (AML). During the first study of enasidenib in humans, a minority of patients with advanced myeloid neoplasms experienced unexpected signs/symptoms of a differentiation syndrome (DS), a potentially lethal entity...
January 18, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29346477/enasidenib-induced-differentiation-syndrome-in-idh2-mutant-acute-myeloid-leukemia
#4
Shyam A Patel
No abstract text is available yet for this article.
January 18, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29346471/use-of-single-nucleotide-polymorphisms-and-mammographic-density-plus-classic-risk-factors-for-breast-cancer-risk-prediction
#5
Elke M van Veen, Adam R Brentnall, Helen Byers, Elaine F Harkness, Susan M Astley, Sarah Sampson, Anthony Howell, William G Newman, Jack Cuzick, D Gareth R Evans
Importance: Single-nucleotide polymorphisms (SNPs) have demonstrated an association with breast cancer susceptibility, but there is limited evidence on how to incorporate them into current breast cancer risk prediction models. Objective: To determine whether a panel of 18 SNPs (SNP18) may be used to predict breast cancer in combination with classic risk factors and mammographic density. Design, Setting, and Participants: This cohort study enrolled a subcohort of 9363 women, aged 46 to 73 years, without a previous breast cancer diagnosis from the larger prospective cohort of the PROCAS study (Predicting Risk of Cancer at Screening) specifically to evaluate breast cancer risk-assessment methods...
January 18, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29346467/modification-of-the-associations-between-duration-of-oral-contraceptive-use-and-ovarian-endometrial-breast-and-colorectal-cancers
#6
Kara A Michels, Ruth M Pfeiffer, Louise A Brinton, Britton Trabert
Importance: Although oral contraceptive (OC) use is common, the influence of OC use on carcinogenesis is not fully understood. A recent Agency for Healthcare Research and Quality report identified a need to understand the consistency of OC use and cancer associations across subpopulations, including smokers and obese women. Objective: To determine whether associations between duration of OC use and risk of specific cancers were modified by lifestyle characteristics...
January 18, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29327061/egfr-tki-associated-interstitial-pneumonitis-in-nivolumab-treated-patients-with-non-small-cell-lung-cancer
#7
Yasuo Oshima, Tetsuya Tanimoto, Koichiro Yuji, Arinobu Tojo
Importance: Nivolumab and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are now the standard-of-care therapies in non-small cell lung cancer (NSCLC). Although EGFR-TKIs are well understood and have well-defined safety profiles, our experience with immune checkpoint inhibitors is still growing, particularly regarding the use of combinations of different classes of antitumor agents, including both the concomitant and sequential use of such agents. Objective: To determine whether nivolumab increases EGFR-TKI-associated interstitial pneumonitis (IP)...
January 11, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29327059/immunotherapy-and-symptomatic-radiation-necrosis-in-patients-with-brain-metastases-treated-with-stereotactic-radiation
#8
Allison M Martin, Daniel N Cagney, Paul J Catalano, Brian M Alexander, Amanda J Redig, Jon D Schoenfeld, Ayal A Aizer
No abstract text is available yet for this article.
January 11, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29327056/neoadjuvant-systemic-therapy-for-breast-cancer-searching-for-more-effectively-curative-therapies
#9
Joseph A Sparano
No abstract text is available yet for this article.
January 11, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29327055/comparing-neoadjuvant-nab-paclitaxel-vs-paclitaxel-both-followed-by-anthracycline-regimens-in-women-with-erbb2-her2-negative-breast-cancer-the-evaluating-treatment-with-neoadjuvant-abraxane-etna-trial-a-randomized-phase-3-clinical-trial
#10
Luca Gianni, Mauro Mansutti, Antonio Anton, Lourdes Calvo, Giancarlo Bisagni, Begoña Bermejo, Vladimir Semiglazov, Marc Thill, Jose Ignacio Chacon, Arlene Chan, Serafin Morales, Isabel Alvarez, Arrate Plazaola, Milvia Zambetti, Andrew D Redfern, Christian Dittrich, Rebecca Alexandra Dent, Domenico Magazzù, Raffaella De Fato, Pinuccia Valagussa, Ignacio Tusquets
Importance: Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling of pathological complete remission (pCR) rates compared with anthracycline-based regimens alone. A reverse sequence did not reduce activity. Nab-paclitaxel is an albumin-bound nanoparticle of paclitaxel that allows for safe infusion without premedication, and its use led to a significantly higher rate of pCR in the GeparSepto trial. Objective: To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting...
January 11, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29327044/association-of-the-lung-immune-prognostic-index-with-immune-checkpoint-inhibitor-outcomes-in-patients-with-advanced-non-small-cell-lung-cancer
#11
Laura Mezquita, Edouard Auclin, Roberto Ferrara, Melinda Charrier, Jordi Remon, David Planchard, Santiago Ponce, Luis Paz Ares, Laura Leroy, Clarisse Audigier-Valette, Enriqueta Felip, Jorge Zerón-Medina, Pilar Garrido, Solenn Brosseau, Gérard Zalcman, Julien Mazieres, Caroline Caramela, Jihene Lahmar, Julien Adam, Nathalie Chaput, Jean Charles Soria, Benjamin Besse
Importance: Derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and lactate dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor (ICI) outcomes in patients with melanoma. Objective: To determine whether pretreatment dNLR and LDH are associated with resistance to ICIs in patients with advanced non-small cell lung cancer (NSCLC). Design, Setting, and Participants: Multicenter retrospective study with a test (n = 161) and a validation set (n = 305) treated with programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors in 8 European centers, and a control cohort (n = 162) treated with chemotherapy only...
January 11, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29327043/association-of-oral-microbiome-with-risk-for-incident-head-and-neck-squamous-cell-cancer
#12
Richard B Hayes, Jiyoung Ahn, Xiaozhou Fan, Brandilyn A Peters, Yingfei Ma, Liying Yang, Ilir Agalliu, Robert D Burk, Ian Ganly, Mark P Purdue, Neal D Freedman, Susan M Gapstur, Zhiheng Pei
Importance: Case-control studies show a possible relationship between oral bacteria and head and neck squamous cell cancer (HNSCC). Prospective studies are needed to examine the temporal relationship between oral microbiome and subsequent risk of HNSCC. Objective: To prospectively examine associations between the oral microbiome and incident HNSCC. Design, Setting, and Participants: This nested case-control study was carried out in 2 prospective cohort studies: the American Cancer Society Cancer Prevention Study II Nutrition Cohort (CPS-II) and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)...
January 11, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29327039/efficacy-and-toxic-effects-of-cancer-immunotherapy-combinations-a-double-edged-sword
#13
Chad Tang, Wen Jiang, Timothy A Yap
No abstract text is available yet for this article.
January 11, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29302695/barriers-to-combined-modality-therapy-for-limited-stage-small-cell-lung-cancer
#14
Todd A Pezzi, David L Schwartz, Abdallah S R Mohamed, James W Welsh, Ritsuko U Komaki, Stephen M Hahn, Boris Sepesi, Christopher M Pezzi, Clifton D Fuller, Stephen G Chun
Importance: Combined-modality therapy with chemotherapy and radiation therapy plays a crucial role in the upfront treatment of patients with limited-stage small-cell lung cancer (SCLC), but there may be barriers to utilization in the United States. Objective: To estimate utilization rates and factors associated with chemotherapy and radiation therapy delivery for limited-stage SCLC using the National Cancer Database. Design, Setting, and Participants: Analysis of initial management of all limited-stage SCLC cases from 2004 through 2013 in the National Cancer Database...
January 4, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29302690/acceptance-in-the-end-of-life
#15
Patrick A Williams
No abstract text is available yet for this article.
January 4, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29302688/the-paradigm-of-escalation-of-commitment-in-treatment-decisions-near-the-end-of-life
#16
Maxwell T Vergo, Amelia M Cullinan, Matthew Wilson
No abstract text is available yet for this article.
January 4, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29302687/breast-implants-and-the-risk-of-anaplastic-large-cell-lymphoma-in-the-breast
#17
Mintsje de Boer, Flora E van Leeuwen, Michael Hauptmann, Lucy I H Overbeek, Jan Paul de Boer, Nathalie J Hijmering, Arthur Sernee, Caroline A H Klazen, Marc B I Lobbes, René R W J van der Hulst, Hinne A Rakhorst, Daphne de Jong
Importance: Breast implants are among the most commonly used medical devices. Since 2008, the number of women with breast implants diagnosed with anaplastic large-cell lymphoma in the breast (breast-ALCL) has increased, and several reports have suggested an association between breast implants and risk of breast-ALCL. However, relative and absolute risks of breast-ALCL in women with implants are still unknown, precluding evidence-based counseling about implants. Objective: To determine relative and absolute risks of breast-ALCL in women with breast implants...
January 4, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29302685/the-hidden-costs-of-medical-education-and-the-impact-on-oncology-workforce-diversity
#18
Neha Vapiwala, Karen M Winkfield
No abstract text is available yet for this article.
January 4, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29302684/autologous-transplantation-for-newly-diagnosed-multiple-myeloma-in-the-era-of-novel-agent-induction-a-systematic-review-and-meta-analysis
#19
Binod Dhakal, Aniko Szabo, Saurabh Chhabra, Mehdi Hamadani, Anita D'Souza, Saad Z Usmani, Rita Sieracki, Bishal Gyawali, Jeffrey L Jackson, Fotis Asimakopoulos, Parameswaran N Hari
Importance: The role of high-dose therapy with melphalan followed by autologous stem cell transplant (HDT/ASCT) in patients with multiple myeloma continues to be debated in the context of novel agent induction. Objective: To perform a systematic review, conventional meta-analysis, and network meta-analysis of all phase 3 randomized clinical trials (RCTs) evaluating the role of HDT/ASCT. Data Sources: We performed a systematic literature search of Cochrane Central, MEDLINE, and Scopus from January 2000 through April 2017 and relevant annual meeting abstracts from January 2014 to December 2016...
January 4, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29302681/the-paradigm-of-escalation-of-commitment-in-treatment-decisions-near-the-end-of-life
#20
Stewart B Fleishman
No abstract text is available yet for this article.
January 4, 2018: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"